Growing pains for Amgen as epoetin wins US approval.
Anderson
A
A
D004345:Drug Industry / Q000191:economics*; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*; D010330:Patents as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D004921:Erythropoietin